Key result
Administration of rAAV expressing an anti-PrPC nanobody in mice exhibited a small but significant therapeutic effect, extending survival time from 176 days to 184 days.
Why the study?
Nanobodies inhibit the conversion of PrPC to PrPSc in vitro, but the potential for in vivo expression and their impact on prion disease required evaluation.
Does ICV injection of anti-PrPC nanobody-expressing rAAV extend survival time in prion-inoculated mice?
Does ICV injection of anti-PrPC nanobody-expressing rAAV extend survival time in prion-inoculated mice?
AAV-mediated delivery of anti-PrPC nanobodies in mice showed a small but statistically significant extension in survival time following prion inoculation, highlighting the need for further optimization.
Answers are grounded in this paper and cite their sources.
Modest survival extension in prion mice warrants caution; leaves open whether AAV-nanobody delivery can be optimized for meaningful benefit.
Prion diseases are fatal neurodegenerative disorders affecting humans and animals, and the central pathogenic event is the conversion of normal prion protein (PrPC) into the pathogenic PrPSc isoform. Previous studies have identified nanobodies that specifically recognize PrPC and inhibit the PrPC to PrPSc conversion in vitro. In this study, we investigated the potential for in vivo expression of anti-PrPC nanobodies and evaluated their impact on prion disease. The coding sequences of three nanobodies were packaged into recombinant adeno-associated virus (rAAV) and were administered via intracerebroventricular (ICV) injection in newborn mice. We found that the expression of these nanobodies remained robust for over 180 days, with no observed detrimental effects. To assess their therapeutic potential, we performed ICV injections of nanobody-expressing rAAVs in newborn mice, followed by intracerebral prion inoculation at 5–6 weeks of age. One nanobody exhibited a small yet statistically significant therapeutic effect, extending survival time from 176 days to 184 days. Analyses of diseased brains revealed that the nanobodies did not alter the pathological changes. Our findings suggest that high levels of anti-PrPC nanobodies are necessary to delay disease progression. Further optimization of the nanobodies, AAV vectors, or delivery methods is essential to achieve a significant therapeutic effect.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2025) studied Prion disease. Anti-PrPC nanobodies packaged into recombinant adeno-associated virus (rAAV) vs. Control (implied) was evaluated on Survival time (p=statistically significant). Administration of rAAV expressing an anti-PrPC nanobody in mice exhibited a small but significant therapeutic effect, extending survival time from 176 days to 184 days.
Synapse has enriched 10 related papers. Consider them for comparative context: